Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.30 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23339267 | 0.95 | ALDH1A1 (0.35) | ALDH1A1MAPT | |
| SCHEMBL23339269 | 0.90 | ALDH1A1 (0.46) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL27417047 | 0.88 | — | — | |
| SCHEMBL23338093 | 0.87 | ALDH1A1 (0.35) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL23338082 | 0.86 | LMNA (0.50) | ALDH1A1MAPTSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL23338088 | 0.86 | LMNA (0.50) | ALDH1A1MAPTSMN1; SMN2LMNAHSD17B10 | |
| SCHEMBL19766564 | 0.82 | LCK (0.31) | TSHR | |
| SCHEMBL115482 | 0.81 | MAPT (0.42) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL23338085 | 0.79 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2LMNAHSD17B10MEN1 | |
| SCHEMBL7927876 | 0.79 | ALDH1A1 (0.39) | ALDH1A1MAPTSMN1; SMN2LMNAHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| EP-1741735-B1 | ANTIOXIDANTS AND RECORDING MEDIA MADE BY USING THE SAME | CANON FINETECH INC (JP) | 2011-10-12 | — | — | EP | disclosed |
| US-7868121-B2 | Antioxidants and recording media by using the same | CANON FINETECH INC. (JP) | 2011-01-11 | — | — | US | disclosed |
| US-20070273716-A1 | Antioxidants And Recording Media By Using The Same | CANON FINETECH NISCA INC. (JP) | 2007-11-29 | — | — | US | disclosed |
| EP-1741735-A1 | ANTIOXIDANTS AND RECORDING MEDIA MADE BY USING THE SAME | Canon Finetech Inc. (JP) | 2007-01-10 | — | — | EP | disclosed |
| US-5603760-A | WITH OXYALKYLENE GLYCOLS, OXYALKYLENE ADDUCTS OF MONOALCOHOLS AND POLYOLS, AND AMMONIUM SALT(S) OF TALL OIL FATTY ACID, CONSTRUCTION MATERIAL WHICH MAINTAINS AIR ENTRAINMENT | W. R. GRACE & CO.-CONN. (US) | 1997-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | ALDH1A1 3448/4885MAPT 4169/4885SMN1; SMN2 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.